These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 31323665)

  • 1. Long-term preservation of measles and rubella specific-IgG antibodies in children with enthesitis related arthritis on anti-TNFα treatment: a prospective controlled study.
    Maritsi DN; Kopsidas I; Vartzelis G; Spyridis N; Tsolia MN
    Rheumatology (Oxford); 2019 Sep; 58(9):1686-1688. PubMed ID: 31323665
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
    Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
    Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
    Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Kulkarni A; Audet S; Mercader S; McGrew M; Hickman CJ; Bellini WJ; Shivakoti R; Griffin DE; Beeler J
    J Infect Dis; 2016 Apr; 213(7):1115-23. PubMed ID: 26597262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
    Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
    J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
    Feldman S; Andrew M; Norris M; McIntyre B; Iyer R
    Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mumps, measles and rubella vaccination in children with PFAPA syndrome.
    Kraszewska-Głomba B; Matkowska-Kocjan A; Miśkiewicz K; Szymańska-Toczek Z; Wójcik M; Banyś D; Szenborn L
    Vaccine; 2016 Nov; 34(48):5903-5906. PubMed ID: 27997341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a robust and standardized immunoserological assay for detection of anti-measles IgG antibodies in human sera.
    Böröcz K; Csizmadia Z; Markovics Á; Mészáros V; Farkas K; Telek V; Varga V; Maloba GO; Bodó K; Najbauer J; Berki T; Németh P
    J Immunol Methods; 2019 Jan; 464():1-8. PubMed ID: 30056035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
    D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
    Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
    Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
    Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of medical students to vaccine-preventable viral diseases: a serological study.
    Kukino J; Naito T; Mitsuhashi K; Oshima H; Sekiya S; Isonuma H; Watanabe K; Dambara T; Hayashida Y
    J Infect Chemother; 2004 Dec; 10(6):335-7. PubMed ID: 15614457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.
    Pebody RG; Gay NJ; Hesketh LM; Vyse A; Morgan-Capner P; Brown DW; Litton P; Miller E
    Vaccine; 2002 Jan; 20(7-8):1134-40. PubMed ID: 11803074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.